Abstract:Accurate drug-target interaction (DTI) prediction is essential for computational drug discovery, yet existing models often rely on single-modality predefined molecular descriptors or sequence-based embeddings with limited representativeness. We propose Tensor-DTI, a contrastive learning framework that integrates multimodal embeddings from molecular graphs, protein language models, and binding-site predictions to improve interaction modeling. Tensor-DTI employs a siamese dual-encoder architecture, enabling it to capture both chemical and structural interaction features while distinguishing interacting from non-interacting pairs. Evaluations on multiple DTI benchmarks demonstrate that Tensor-DTI outperforms existing sequence-based and graph-based models. We also conduct large-scale inference experiments on CDK2 across billion-scale chemical libraries, where Tensor-DTI produces chemically plausible hit distributions even when CDK2 is withheld from training. In enrichment studies against Glide docking and Boltz-2 co-folder, Tensor-DTI remains competitive on CDK2 and improves the screening budget required to recover moderate fractions of high-affinity ligands on out-of-family targets under strict family-holdout splits. Additionally, we explore its applicability to protein-RNA and peptide-protein interactions. Our findings highlight the benefits of integrating multimodal information with contrastive objectives to enhance interaction-prediction accuracy and to provide more interpretable and reliability-aware models for virtual screening.
Abstract:Simultaneously optimizing molecules against multiple therapeutic targets remains a profound challenge in drug discovery, particularly due to sparse rewards and conflicting design constraints. We propose a structured active learning (AL) paradigm integrating a sequence-to-sequence (Seq2Seq) variational autoencoder (VAE) into iterative loops designed to balance chemical diversity, molecular quality, and multi-target affinity. Our method alternates between expanding chemically feasible regions of latent space and progressively constraining molecules based on increasingly stringent multi-target docking thresholds. In a proof-of-concept study targeting three related coronavirus main proteases (SARS-CoV-2, SARS-CoV, MERS-CoV), our approach efficiently generated a structurally diverse set of pan-inhibitor candidates. We demonstrate that careful timing and strategic placement of chemical filters within this active learning pipeline markedly enhance exploration of beneficial chemical space, transforming the sparse-reward, multi-objective drug design problem into an accessible computational task. Our framework thus provides a generalizable roadmap for efficiently navigating complex polypharmacological landscapes.